Denali Therapeutics (DNLI) said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals (TAK) terminated their joint development agreement.

Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.

Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.

Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.

Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.